BioMedPartners
BioMedPartners is one of the leading European venture capital firms.
Business Model:
Revenue: $12.6M
Employees: 2-10
Rankings
Industries / Tags:
Detailed BioMedPartners Information
Geographic Data
Address: Elisabethenstr. 23
City: Basel
State: basel-country
Zip: 4051
Country: CH
Financial Info
Stage:
Raised Last:
$0
Raised Total:$75M
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 6/2018 | Tricares | Series B | 25.7M |
| 12/2019 | ImmunOs Therapeutics | Series A | 0 |
| 4/2010 | Affimed | Series C | 0 |
| 12/2009 | Evolva | Post-IPO Equity | 27.5M |
| 11/2003 | Thommen Medical | Series C | 0 |
| 3/2011 | Anergis | Series A | 20M |
| 12/2016 | Hookipa Pharma | Series B | 10.7M |
| 5/2013 | SuppreMol | Series D | 12.3M |
| 10/2009 | Evolva | Series B | 27.8M |
| 12/2014 | AYOXXA | Series B | 2.9M |
| 3/2022 | Scenic Biotech | Series A | 0 |
| 7/2021 | Topas Therapeutics | Series B | 0 |
| 11/2014 | Humedics | Series C | 7.8M |
| 11/2018 | Precirix | Series A | 41.9M |
| 10/2006 | Santhera Pharmaceuticals | Series C | 0 |
| 12/2019 | Aleva Neurotherapeutics | Series E | 8.1M |
| 11/2003 | Roche Glycart | Series A | 13.6M |
| 9/2018 | TOLREMO therapeutics | Series A | 9.3M |
| 12/2007 | Vivendy Therapeutics | Series A | 15.4M |
| 10/2015 | Sequana Medical | Series C | 0 |
| 10/2013 | Middle Peak Medical | Series A | 0 |
| 1/2018 | Miracor Medical | Series D | 0 |
| 10/2016 | Miracor Medical | Series C | 0 |
| 12/2014 | Anergis | Series B | 14.9M |
| 2/2006 | EyeSense AG | Series A | 0 |
| 1/2015 | Miracor Medical | Series B | 5.3M |
| 3/2007 | Okairos | Series A | 9.6M |
| 11/2014 | Curetis | Series B | 0 |
| 9/2005 | Bioheart | Venture Round | 0 |
| 4/2014 | Sequana Medical | Series C | 26.1M |
| 3/2014 | Inotrem | Series A | 25.1M |
| 8/2005 | Dolthera GmbH | Series B | 18M |
| 9/2005 | Spinal Cord Therapeutics GmbH | Series A | 15.5M |
| 4/2007 | Affimed | Series B | 32M |
| 10/2012 | Affimed | Series D | 20.1M |
| 2/2014 | Anergis | Series A | 8.9M |
| 12/2009 | Curetis | Series A | 27.9M |
| 9/2022 | Tricares | Series C | 0 |
| 11/2013 | Hookipa Pharma | Series B | 27M |
| 8/2009 | Spinelab | Series B | 10.2M |
| 4/2007 | Spinelab | Series A | 3.3M |
| 3/2011 | Sequana Medical | Series B | 25.5M |
| 1/2015 | Genkyotex | Post-IPO Equity | 0 |
| 8/2008 | ESBATech | Series B | 22M |
| 10/2007 | idiag | Venture Round | 3.8M |
| 8/2006 | ESBATech | Series B | 41M |
| 10/2014 | ImevaX | Series A | 0 |
| 12/2017 | Hookipa Pharma | Series C | 0 |
| 10/2020 | Topas Therapeutics | Series B | 0 |
| 5/2017 | Cardior Pharmaceuticals | Series A | 16.3M |
| 2/2020 | Azafaros | Series A | 27.5M |
| 3/2004 | 4-Antibody AG | Seed Round | 2.1M |
| 4/2019 | Alentis Therapeutics | Series A | 12.3M |
| 4/2012 | Aleva Neurotherapeutics | Series B | 4.4M |
| 7/2008 | SuppreMol | Series B | 25M |
| 3/2004 | CareX SA | Series B | 32M |
| 5/2022 | Tubulis | Series B | 0 |
| 6/2022 | ImmunOs Therapeutics | Series B | 0 |
| 7/2020 | Tubulis | Series A | 12.3M |
| 12/2020 | Noema Pharma | Series A | 60M |
| 3/2022 | Precirix | Series B | 0 |
| 11/2013 | Delenex Therapeutics | Series A | 8M |
| 9/2017 | Amal Therapeutics | Series B | 9.5M |
| 11/2018 | Amal Therapeutics | Series B | 32.6M |
| 1/2011 | VAXIMM | Venture Round | 8M |
| 5/2012 | Spinelab | Series C | 4.8M |
| 9/2008 | Lumavita | Series A | 16.2M |
| 8/2021 | Cardior Pharmaceuticals | Series B | 0 |
| 11/2009 | Activaero | Series A | 15.8M |
| 11/2010 | Delenex Therapeutics | Series A | 14M |
| 2/2011 | Activaero | Series A | 0 |
| 11/2004 | Symetis | Series A | 9.6M |
| 12/2010 | SuppreMol | Series C | 20.4M |
| 9/2014 | Affimed | Series E | 0 |
| 6/2021 | Alentis Therapeutics | Series B | 66.8M |
| 8/2011 | Aleva Neurotherapeutics | Series A | 13.7M |
| 6/2020 | TOLREMO therapeutics | Series A | 5M |
| 5/2011 | Delenex Therapeutics | Series A | 19.3M |
| 4/2016 | Anergis | Series C | 5.2M |
| 5/2016 | Aleva Neurotherapeutics | Series C | 18M |
| 6/2022 | ImmunOs Therapeutics | Series B | 0 |
| 5/2022 | Tubulis | Series B | 0 |
| 3/2022 | Precirix | Series B | 0 |
| 3/2022 | Scenic Biotech | Series A | 0 |
| 8/2021 | Cardior Pharmaceuticals | Series B | 0 |
| 7/2021 | Topas Therapeutics | Series B | 0 |
| 6/2021 | Alentis Therapeutics | Series B | 0 |
| 12/2020 | Noema Pharma | Series A | 0 |
| 10/2020 | Topas Therapeutics | Series B | 0 |
| 7/2020 | Tubulis | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
